Pulmatrix Shifts Focus Amid Merger Termination, Seeks New Strategic Partnerships

Pulmatrix Faces Merger Setback, Shifts Focus to New Opportunities

In a significant development for Pulmatrix, Inc., the company learns of the termination of its Merger Agreement with Cullgen Inc. as of February 28, 2026. This decision follows a series of delays related to the China Securities Regulatory Commission (CSRC), which began impacting the merger process in 2025. The agreement, initially established on November 13, 2024, faced various amendments, including a modification in April 2025 that enabled both parties to bypass a "No Solicitation" clause. The merger had garnered shareholder approval during a special meeting on June 16, 2025, with expectations that it would significantly enhance Pulmatrix's capabilities and market position in the biopharmaceutical field.

The culmination of regulatory hurdles, particularly the lack of CSRC approval, ultimately led Cullgen to terminate the merger. Given this setback, Pulmatrix’s Interim CEO, Peter Ludlum, remains optimistic about the potential for new partnerships, emphasizing the growing interest in merger activities within the industry. He indicates that despite the termination, the company is exploring alternative merger opportunities while maintaining its commitment to innovative inhaled therapeutics, including treatments for migraines and respiratory diseases through its proprietary iSPERSE™ technology. The technology's licensing to MannKind Corporation and Cipla Technologies further underscores Pulmatrix's strategic value in the market.

With the termination of the merger, Pulmatrix is not deterred from seeking innovative solutions to continue driving growth. The company focuses on its core mission of addressing significant unmet medical needs using its advanced therapeutic platform, which has been highlighted in SEC disclosure documents. The proactive search for new collaborations aligns with the broader trends within the biopharmaceutical industry and reflects Pulmatrix's resilience in the face of challenges.

In related activity, the biopharmaceutical sector shows signs of increased merger and acquisition interest, signifying a potentially favorable environment for Pulmatrix to secure new alliances. Given the pivotal role of innovation in addressing healthcare challenges, Pulmatrix's pursuit of alternative strategies aligns with industry dynamics aimed at advancing therapeutic solutions for patients. As it navigates these changes, Pulmatrix remains committed to enhancing its business model and driving positive outcomes within the healthcare landscape.